tbuckley/cabot-search huggingface dataset:
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218
Authors: Angeles Alvarez Secord, Kirsten Bell Burdett, Kouros Owzar, David Tritchler, Alexander B. Sibley, Yingmiao Liu, Mark D. Starr, J. Chris Brady, Heather A. Lankes, Herbert I. Hurwitz, Robert S. Mannel, Krishnansu S. Tewari, David M. O'Malley, Heidi Gray, Jamie N. Bakkum-Gamez, Keiichi Fujiwara, Matthew Boente, Wei Deng, Robert A. Burger, Michael J. Birrer, Andrew B. Nixon
Journal: Clinical Cancer Research (2020)

GOG-0218, a double-blind placebo-controlled phase III trial, compared carboplatin and paclitaxel with placebo, bevacizumab followed by placebo, or bevacizumab followed by bevacizumab in advanced epithelial ovarian cancer (EOC). Results demonstrated significantly improved progression-free survival (PFS), but no overall survival (OS) benefit with bevacizumab. Blood samples were collected for biomarker analyses.
Corrections to “Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
Authors: C. Marth, F. Landoni, S. Mahner, M. McCormack, A. Gonzalez-Martin, N. Colombo
Journal: Annals of Oncology (2018)

Ann Oncol 2017; 28: iv72–iv83 (doi:10.1093/annonc/mdx220) Under the section “Adjuvant treatment” Adjuvant treatment Women with risk factors on the pathology specimen should receive adjuvant therapy following hysterectomy (Table 3). Two classes of risk are defined: intermediate- and high-risk patients. Is replaced with: Adjuvant treatment (Table 3) Two classes of risk are defined: intermediate- and high-risk patients. In “Table 5. Summary of recommendations” Adjuvant treatment•Women with intermediate- and high-risk factors on the pathology specimen should receive adjuvant therapy following hysterectomy (see Table 3).•Cervical cancer patients with intermediate-risk disease do not need further adjuvant therapy [II, B], whereas adjuvant CRT is recommended in high-risk patients [I, A]. Is replaced with: Adjuvant treatment•Cervical cancer patients with intermediate-risk disease do not need further adjuvant therapy [II, B], whereas adjuvant CRT is recommended in high-risk patients [I, A]. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of OncologyVol. 28PreviewCervical cancer is the second most commonly diagnosed cancer and the third leading cause of cancer death among females in less developed countries. There were an estimated 527 600 new cervical cancer cases and 265 700 deaths worldwide in 2012 [1]. Nearly 90% of cervical cancer deaths occurred in developing parts of the world. The large geographic variation in cervical cancer rates reflects differences in the availability of screening (which allows for the detection and removal of precancerous lesions) and in human papillomavirus (HPV) infection prevalence. Full-Text PDF Open Archive
Amplification of OCT4-Pseudogene POU5F1B is a Poor Prognostic Factor in Gastric Cancer
Authors: H. Hayashi, T. Arao, K. Matsumoto, T. Nagai, H. Kimura, M.A. De Velasco, Y. Fujita, Y. Yamada, K. Nakagawa, K. Nishio
Journal: Annals of Oncology (2012)
Integrated proteogenomic approach identifying a protein signature of COPD and a new splice variant of SORBS1
Authors: Corry-Anke Brandsma, Victor Guryev, Wim Timens, Ana Ciconelle, Dirkje S Postma, Rainer Bischoff, Maria Johansson, Ekaterina S Ovchinnikova, Johan Malm, Gyorgy Marko-Varga, Thomas E Fehniger, Maarten van den Berge, Peter Horvatovich
Journal: Thorax (2020)

Translation of genomic alterations to protein changes in chronic obstructive pulmonary disease (COPD) is largely unexplored. Using integrated proteomic and RNA sequencing analysis of COPD and control lung tissues, we identified a protein signature in COPD characterised by extracellular matrix changes and a potential regulatory role for SUMO2. Furthermore, we identified 61 differentially expressed novel, non-reference, peptides in COPD compared with control lungs. This included two peptides encoding for a new splice variant of SORBS1, of which the transcript usage was higher in COPD compared with control lungs. These explorative findings and integrative proteogenomic approach open new avenues to further unravel the pathology of COPD.
A Large Retrospective Analysis of the Activity of Pemetrexed (PEM) in Patients (Patients) with ALK+ NSCLC Before Crizotinib (CRIZ)
Authors: G.V. Scagliotti, D.-W. Kim, A.T. Shaw, S.-H.I. Ou, G.J. Riely, S.N. Gettinger, B. Besse, M. Thomas, R. Salgia, K. Wilner, C.H. Bartlett, A. Polli, D.R. Gandara
Journal: Annals of Oncology (2012)
Food aversion and poor weight gain in food protein–induced enterocolitis syndrome: A retrospective study
Authors: Kuan-Wen Su, Sarita U. Patil, Jennifer L. Stockbridge, Victoria M. Martin, Yamini V. Virkud, Jing-Long Huang, Wayne G. Shreffler, Qian Yuan
Journal: Journal of Allergy and Clinical Immunology (2020)
The Analytical Validation of Prostate Specific Mrna Detection in Whole Blood by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) as a Prognostic Biomarker for Patients with Castration-Resistant Prostate Cancer (CRPC)
Authors: D. Danila, A. Anand, G. Heller, M. Wan, M. Zehnder, R. Khanin, N. Schultz, M. Fleisher, H. Lilja, H.I. Scher
Journal: Annals of Oncology (2012)
A Retrospective Analysis of Chemotherapy with S-1 after the Standard Treatment of Non-Small-Cell Lung Cancer
Authors: Y. Seki, A. Kinoshita, M. Gouchi, Z. Saito, Y. Yoshii, T. Samejima, A. Seki, Y. Kaneko, H. Takeda, K. Kuwano
Journal: Annals of Oncology (2012)
Palonostron with Aprepitant–Dexamethasone to Prevent Chemotherapy-Induced Nausea and Vomiting During Gemcitabine/Cisplatin in Urothelial Cancer Patients
Authors: H. Kitamura, F. Fukuta, N. Nishiyama, T. Tanaka, N. Masumori, T. Tsukamoto
Journal: Annals of Oncology (2012)
Association of Insurance Status and Racial Disparities With the Detection of Early-Stage Breast Cancer
Authors: Naomi Y. Ko, Susan Hong, Robert A. Winn, Gregory S. Calip
Journal: JAMA Oncology (2020)

<h3>Importance</h3> Compared with non-Hispanic white women, racial/ethnic minority women receive a diagnosis of breast cancer at a more advanced stage and have higher morbidity and mortality with breast cancer diagnosis. Access to care with adequate insurance may be associated with earlier diagnosis, expedited treatment, and improved prognosis. <h3>Objective</h3> To examine the extent to which insurance is associated with access to timely breast cancer diagnosis and breast cancer stage differences among a large, diverse population of US patients with breast cancer. <h3>Design, Setting, and Participants</h3> This retrospective, cross-sectional population-based study used data from the Surveillance, Epidemiology, and End Results Program on 177 075 women aged 40 to 64 years who received a diagnosis of stage I to III breast cancer between January 1, 2010, and December 31, 2016. Statistical analysis was performed from August 1, 2017, to October 1, 2019. <h3>Main Outcomes and Measures</h3> The primary outcome was the risk of having a more advanced stage of breast cancer at diagnosis (ie, stage III vs stages I and II). Mediation analyses were conducted to determine associations of race/ethnicity and proportion of observed differences mediated by health insurance status with earlier stage of diagnosis. <h3>Results</h3> A total of 177 075 women (mean [SD] age, 53.5 [6.8] years; 148 124 insured and 28 951 uninsured or receiving Medicaid) were included in the study. A higher proportion of women either receiving Medicaid or who were uninsured received a diagnosis of locally advanced breast cancer (stage III) compared with women with health insurance (20% vs 11%). In multivariable models, non-Hispanic black (odds ratio [OR], 1.46 [95% CI, 1.40-1.53]), American Indian or Alaskan Native (OR, 1.31 [95% CI, 1.07-1.61]) and Hispanic (OR, 1.35 [95% CI, 1.30-1.42]) women had higher odds of receiving a diagnosis of locally advanced disease (stage III) compared with non-Hispanic white women. When adjusting for health insurance and other socioeconomic factors, associations between race/ethnicity and risk of locally advanced breast cancer were attenuated (non-Hispanic black: OR, 1.29 [95% CI, 1.23-1.35]; American Indian or Alaskan Native: OR, 1.11 [95% CI, 0.91-1.35]; Hispanic: OR, 1.17 [95% CI, 1.12-1.22]). Nearly half (45%-47%) of racial differences in the risk of locally advanced disease were mediated by health insurance. <h3>Conclusions and Relevance</h3> This study’s findings suggest that nearly half of the observed racial/ethnic disparities in higher stage at breast cancer diagnosis are mediated by health insurance coverage.
Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence
Authors: Wiebke Pruessmann, Julie Rytlewski, James Wilmott, Martin C. Mihm, Grace H. Attrill, Beatrice Dyring-Andersen, Paul Fields, Qian Zhan, Andrew J. Colebatch, Peter M. Ferguson, John F. Thompson, Klaus Kallenbach, Erik Yusko, Rachael A. Clark, Harlan Robins, Richard A. Scolyer, Thomas S. Kupper
Journal: Nature Cancer (2020)
Population-Based Approaches to Mental Health: History, Strategies, and Evidence
Authors: Jonathan Purtle, Katherine L. Nelson, Nathaniel Z. Counts, Michael Yudell
Journal: Annual Review of Public Health (2020)

There is growing recognition in the fields of public health and mental health services research that the provision of clinical services to individuals is not a viable approach to meeting the mental health needs of a population. Despite enthusiasm for the notion of population-based approaches to mental health, concrete guidance about what such approaches entail is lacking, and evidence of their effectiveness has not been integrated. Drawing from research and scholarship across multiple disciplines, this review provides a concrete definition of population-based approaches to mental health, situates these approaches within their historical context in the United States, and summarizes the nature of these approaches and their evidence. These approaches span three domains: (a) social, economic, and environmental policy interventions that can be implemented by legislators and public agency directors, (b) public health practice interventions that can be implemented by public health department officials, and (c) health care system interventions that can be implemented by hospital and health care system leaders.
Development and Validation of a Robust Molecular Diagnostic Test (COLOPRINT) for Predicting Outcome in Stage II Colon Cancer Patients
Authors: T. Bachleitner-Hofmann, I. Simon, R. Salazar, J. Tabernero, R. Rosenberg, J. van der Akker, Y. Li, B. Chan, G. Lanza, A. Glas
Journal: Annals of Oncology (2012)
Collecting system–specific deletion of Kcnj10 predisposes for thiazide- and low-potassium diet–induced hypokalemia
Authors: David Penton, Twinkle Vohra, Eszter Banki, Agnieszka Wengi, Maria Weigert, Anna-Lena Forst, Sascha Bandulik, Richard Warth, Johannes Loffing
Journal: Kidney International (2020)
Neoadjuvant Chemotherapy in Operable Breast Cancer: Data From the Aster Study (At for 3 Cycles Followed by CMF for 3 Cycles)
Authors: E. Puma, P. Mariani, S. Damian, M.C. Dazzani, E. De Benedictis, M. Parati, L. Sica, A. Tessari, F.G.M. De Braud, A. Moliterni
Journal: Annals of Oncology (2012)
Paediatricians should talk to families about reducing exposure and contribution to air pollution
Authors: Elisabeth Mahase
Journal: BMJ (2020)

Paediatricians and other health professionals should talk to patients and families about how they can reduce exposure and contribution to air pollution, the Royal College of Paediatrics and Child Health (RCPCH) has said.

The college has published new information to help paediatricians have these discussions. It recommends that children, young people, and families take actions such as walking or cycling short journeys instead of taking the car, walking on quieter streets rather than main roads, and taking public transport for longer journeys. …
Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study
Authors: Wouter Bulten, Hans Pinckaers, Hester van Boven, Robert Vink, Thomas de Bel, Bram van Ginneken, Jeroen van der Laak, Christina Hulsbergen-van de Kaa, Geert Litjens
Journal: The Lancet Oncology (2020)
Glaucoma report: patients’ sight is put at risk by treatment delays
Authors: Ingrid Torjesen
Journal: BMJ (2020)

Patients with glaucoma in England are experiencing severe and permanent sight loss because their condition is not being monitored properly owing to staff shortages in hospital eye services, an independent investigation has found.1

The Healthcare Safety Investigation Branch (HSIB), which investigates patient safety concerns related to NHS care in England, found that eye services did not have the capacity to meet demand for glaucoma services. It said that capacity could be freed up by introducing mechanisms to ensure appropriate referral to and follow-up by hospital eye services, as well as through new ways of working to free up consultants’ time, such as redesigning pathways so that other members of the multidisciplinary team could take on …
Phase I Trial of Combination Chemotherapy of Pemetrexed (PEM) Plus Cisplatin (CDDP) and Concurrent Thoracic Radiotherapy (TRT) Followed by PEM Consolidation Therapy in Patients with Locally Advanced Non-Squamous (NON-SQ) Non-Small-Cell Lung Cancer (NSCLC): Post-Hoc Analysis for Progression-Free Survival (PFS) and Recurrent Sites
Authors: S. Niho, H. Nokihara, K. Nihei, T. Akimoto, M. Sumi, Y. Ito, K. Yoh, K. Goto, H. Ohmatsu, H. Horinouchi, N. Yamamoto, I. Sekine, K. Kubota, Y. Ohe, T. Tamura
Journal: Annals of Oncology (2012)
P-0173 Thymidilate Synthase (TS) and Excision Repair Complementation Group 1 (ERCC1) Status And Clinicopathologic Factors in Gastro-Intestinal Cancer
Authors: Ali Motlagh, Farnaz Hosseini Kamal, Seyed Ahmad Aleyasin, Payam Azadeh, Christer Larsson, Mitra Rafizadeh, Mohamad Hashemi, Naser Rakhshani, Saadat Molanaei
Journal: Annals of Oncology (2012)
Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus
Authors: Tiphaine Delaunay, Carole Achard, Nicolas Boisgerault, Marion Grard, Tacien Petithomme, Camille Chatelain, Soizic Dutoit, Christophe Blanquart, Pierre-Joseph Royer, Stéphane Minvielle, Lisa Quetel, Clément Meiller, Didier Jean, Delphine Fradin, Jaafar Bennouna, Antoine Magnan, Laurent Cellerin, Frédéric Tangy, Marc Grégoire, Jean-François Fonteneau
Journal: Journal of Thoracic Oncology (2020)
Failure to challenge discriminatory behaviour is complicity
Authors: Jessica Potter
Journal: BMJ (2020)

Like other female doctors, I have long been accustomed to the assumption that I am a nurse. But I am frequently disappointed by the silence of male witnesses to these everyday acts of sexism.1 On a ward round recently, I and another senior (male) registrar flanked the male consultant, stethoscopes around our necks. We gave our opinions while three male juniors …
Fecal Microbiota Transplant Decreases Mortality in Patients with Refractory Severe or Fulminant Clostridioides difficile Infection
Authors: Yao-Wen Cheng, Emmalee Phelps, Sara Nemes, Nicholas Rogers, Sashidhar Sagi, Matthew Bohm, Mustapha El-Halabi, Jessica R. Allegretti, Zain Kassam, Huiping Xu, Monika Fischer
Journal: Clinical Gastroenterology and Hepatology (2020)
Assessment Of Circulating Free DNA (CFDNA) and Circulating Melanoma Cells (CMCS) as Prognostic Biomarkers in Metastatic Cutaneous Melanoma
Authors: K. Aung, L.T. Khoja, C. Zhou, M. Lancashire, R. Sloane, G. Brady, G. Clack, A. Hughes, P. Lorigan, C. Dive
Journal: Annals of Oncology (2012)
Bariatric Surgery Is Safe and It Works
Authors: Anne P. Ehlers, Amir A. Ghaferi
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Erlotinib (ERL) versus Pemetrexed (MTA) as Second-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer (NSNSCLC): Efficacy and Safety Data
Authors: J. Zugazagoitia, J. Puente, S. Hernandez, J.L. Gonzalez-Larriba, J. Sanz, A. Manzano, E. Diaz-Rubio
Journal: Annals of Oncology (2012)
Association of Early Palliative Care With Survival in Patients With Advanced Lung Cancer
Authors: Marko Skelin, Eugen Javor, Marko Lucijanic
Journal: JAMA Oncology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Editor's Note: Dominant-Negative Fas Mutation Is Reversed by Down-expression of c-FLIP
Authors: Marie Bénéteau, Sophie Daburon, Jean-François Moreau, Jean-Luc Taupin, Patrick Legembre
Journal: Cancer Research (2020)

The editors are publishing this note to alert readers to concerns about [this article][1] ([1][2]). The same Western blot analysis image was used for Jurkat-R cells in Fig. 4A and for Jurkat parental cells in Fig. 1B of another article previously published by the authors ([2][3]). In addition, lane
P-0257 Bevacizumab Effectiveness in First-Line Treatment of Metastatic Colorectal Cancer, in Relation to Kras Expression and Metastatic Sites
Authors: Luigi Rossi, Enzo Veltri, Angelo Zullo, Federica Zoratto, Maria Colonna, Gabriella Del Bene, Marcella Mottolese, Diana Giannarelli, Luigi Ruco, Adriana Romiti, Viola Barucca, Daniela Adua, Giancarlo Arcangeli, Roberto Cianni, Giuseppe Giannini, Marco Sacchi, Silverio Tomao
Journal: Annals of Oncology (2012)
High Dietary Intake of Vegetable or Polyunsaturated Fats Is Associated With Reduced Risk of Hepatocellular Carcinoma
Authors: Wanshui Yang, Jing Sui, Yanan Ma, Tracey G. Simon, Jessica L. Petrick, Michelle Lai, Katherine A. McGlynn, Peter T. Campbell, Edward L. Giovannucci, Andrew T. Chan, Xuehong Zhang
Journal: Clinical Gastroenterology and Hepatology (2020)
Effect of Weight Loss on Upper Airway Anatomy and the Apnea–Hypopnea Index. The Importance of Tongue Fat
Authors: Stephen H. Wang, Brendan T. Keenan, Andrew Wiemken, Yinyin Zang, Bethany Staley, David B. Sarwer, Drew A. Torigian, Noel Williams, Allan I. Pack, Richard J. Schwab
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

Rationale: Obesity is the primary risk factor for obstructive sleep apnea (OSA). Tongue fat is increased in obese persons with OSA, and may explain the relationship between obesity and OSA. Weight loss improves OSA, but the mechanism is unknown.Objectives: To determine the effect of weight loss on upper airway anatomy in subjects with obesity and OSA. We hypothesized that weight loss would decrease soft tissue volumes and tongue fat, and that these changes would correlate with reductions in apnea–hypopnea index (AHI).Methods: A total of 67 individuals with obesity and OSA (AHI ≥ 10 events/h) underwent a sleep study and upper airway and abdominal magnetic resonance imaging before and after a weight loss intervention (intensive lifestyle modification or bariatric surgery). Airway sizes and soft tissue, tongue fat, and abdominal fat volumes were quantified. Associations between weight loss and changes in these structures, and relationships to AHI changes, were examined.Measurements and Main Results: Weight loss was significantly associated with reductions in tongue fat and pterygoid and total lateral wall volumes. Reductions in tongue fat were strongly correlated with reductions in AHI (Pearson’s rho = 0.62, P < 0.0001); results remained after controlling for weight loss (Pearson’s rho = 0.36, P = 0.014). Reduction in tongue fat volume was the primary upper airway mediator of the relationship between weight loss and AHI improvement.Conclusions: Weight loss reduced volumes of several upper airway soft tissues in subjects with obesity and OSA. Improved AHI with weight loss was mediated by reductions in tongue fat. New treatments that reduce tongue fat should be considered for patients with OSA.